19 June 2013
Keywords: roche, chugai, hep, drug, under, priority, review
Article | 19 September 2005
Swiss drug major Roche and its wholly-owned Japanese subsidiary Chugai say that the combination of Pegasys (peginterferon alfa-2a 40KD) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 September 2005
18 June 2013
© 2013 thepharmaletter.com